ZelandeDVT的临床疗效™ 导管溶栓治疗亚急性深静脉血栓形成患者的单次治疗。

IF 1.6 4区 医学 Q3 PERIPHERAL VASCULAR DISEASE
Phlebology Pub Date : 2023-09-01 Epub Date: 2023-07-12 DOI:10.1177/02683555231188900
Da Li, Xiaosong Zhang, Yusheng Wang, Hao Tang, He Huang, Xiaomin Huang, Honggang Zhang
{"title":"ZelandeDVT的临床疗效™ 导管溶栓治疗亚急性深静脉血栓形成患者的单次治疗。","authors":"Da Li,&nbsp;Xiaosong Zhang,&nbsp;Yusheng Wang,&nbsp;Hao Tang,&nbsp;He Huang,&nbsp;Xiaomin Huang,&nbsp;Honggang Zhang","doi":"10.1177/02683555231188900","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the clinical efficacy and safety of novel ZelanteDVT™ catheter rheolytic thrombectomy in the single-session endovascular management of subacute deep venous thrombosis (DVT).</p><p><strong>Methods: </strong>A retrospective study was performed on 31 patients with subacute DVT who underwent ZelanteDVT™ catheter rheolytic thrombectomy. Procedure data, associated complications, and venous patency score were recorded. The deep venous patency and post-thrombotic syndrome (PTS) rate were assessed in all patients during follow-up visits.</p><p><strong>Results: </strong>After procedure, 19.4% (6/31) patients improved to grade III thrombus removal, while the remaining patients improved to grade II. Significant iliac vein compression syndrome was identified in 54.8% (17/31) patients, and 82.4% (14/17) of them received stent implantation. No serious procedure-related complications occurred. The median follow-up time was 13 months. The primary patency rate at 12 months was 83.87%, and the incidence of PTS was 19.35%.</p><p><strong>Conclusion: </strong>This novel rheological thrombectomy catheter seems to have a promising application prospect for single-session treatment of subacute DVT.</p>","PeriodicalId":20139,"journal":{"name":"Phlebology","volume":" ","pages":"523-531"},"PeriodicalIF":1.6000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical efficacy of ZelanteDVT™ catheter rheolytic thrombectomy in the single-session treatment of patients with subacute deep venous thrombosis.\",\"authors\":\"Da Li,&nbsp;Xiaosong Zhang,&nbsp;Yusheng Wang,&nbsp;Hao Tang,&nbsp;He Huang,&nbsp;Xiaomin Huang,&nbsp;Honggang Zhang\",\"doi\":\"10.1177/02683555231188900\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To evaluate the clinical efficacy and safety of novel ZelanteDVT™ catheter rheolytic thrombectomy in the single-session endovascular management of subacute deep venous thrombosis (DVT).</p><p><strong>Methods: </strong>A retrospective study was performed on 31 patients with subacute DVT who underwent ZelanteDVT™ catheter rheolytic thrombectomy. Procedure data, associated complications, and venous patency score were recorded. The deep venous patency and post-thrombotic syndrome (PTS) rate were assessed in all patients during follow-up visits.</p><p><strong>Results: </strong>After procedure, 19.4% (6/31) patients improved to grade III thrombus removal, while the remaining patients improved to grade II. Significant iliac vein compression syndrome was identified in 54.8% (17/31) patients, and 82.4% (14/17) of them received stent implantation. No serious procedure-related complications occurred. The median follow-up time was 13 months. The primary patency rate at 12 months was 83.87%, and the incidence of PTS was 19.35%.</p><p><strong>Conclusion: </strong>This novel rheological thrombectomy catheter seems to have a promising application prospect for single-session treatment of subacute DVT.</p>\",\"PeriodicalId\":20139,\"journal\":{\"name\":\"Phlebology\",\"volume\":\" \",\"pages\":\"523-531\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Phlebology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/02683555231188900\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/7/12 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"PERIPHERAL VASCULAR DISEASE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Phlebology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/02683555231188900","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/7/12 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0

摘要

目的:评价新型ZelandeDVT的临床疗效和安全性™ 导管溶栓术在亚急性深静脉血栓形成(DVT)单次血管内治疗中的应用方法:对31例接受ZelandeDVT的亚急性DVT患者进行回顾性研究™ 导管溶栓血栓切除术。记录手术数据、相关并发症和静脉通畅性评分。在随访期间评估所有患者的深静脉通畅率和血栓形成后综合征(PTS)发生率。结果:术后,19.4%(6/31)的患者病情好转至III级血栓清除,其余患者病情好转为II级。54.8%(17/31)的患者发现了严重的髂静脉压迫综合征,其中82.4%(14/17)的患者接受了支架植入。没有发生严重的手术并发症。中位随访时间为13个月。12个月时初次通畅率为83.87%,PTS发生率为19.35%。结论:这种新型流变性血栓切除导管在亚急性DVT的单次治疗中具有良好的应用前景。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Clinical efficacy of ZelanteDVT™ catheter rheolytic thrombectomy in the single-session treatment of patients with subacute deep venous thrombosis.

Objective: To evaluate the clinical efficacy and safety of novel ZelanteDVT™ catheter rheolytic thrombectomy in the single-session endovascular management of subacute deep venous thrombosis (DVT).

Methods: A retrospective study was performed on 31 patients with subacute DVT who underwent ZelanteDVT™ catheter rheolytic thrombectomy. Procedure data, associated complications, and venous patency score were recorded. The deep venous patency and post-thrombotic syndrome (PTS) rate were assessed in all patients during follow-up visits.

Results: After procedure, 19.4% (6/31) patients improved to grade III thrombus removal, while the remaining patients improved to grade II. Significant iliac vein compression syndrome was identified in 54.8% (17/31) patients, and 82.4% (14/17) of them received stent implantation. No serious procedure-related complications occurred. The median follow-up time was 13 months. The primary patency rate at 12 months was 83.87%, and the incidence of PTS was 19.35%.

Conclusion: This novel rheological thrombectomy catheter seems to have a promising application prospect for single-session treatment of subacute DVT.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Phlebology
Phlebology 医学-外周血管病
CiteScore
3.30
自引率
11.80%
发文量
84
审稿时长
6-12 weeks
期刊介绍: The leading scientific journal devoted entirely to venous disease, Phlebology is the official journal of several international societies devoted to the subject. It publishes the results of high quality studies and reviews on any factor that may influence the outcome of patients with venous disease. This journal provides authoritative information about all aspects of diseases of the veins including up to the minute reviews, original articles, and short reports on the latest treatment procedures and patient outcomes to help medical practitioners, allied health professionals and scientists stay up-to-date on developments. Print ISSN: 0268-3555
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信